1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Skin Cancer-Pipeline Insights, 2017

Skin Cancer-Pipeline Insights, 2017

  • January 2017
  • -
  • Delve Insight


DelveInsight’s, “ Skin Cancer-Pipeline Insights, 2017”, report provides in depth insights on the pipeline drugs and their development activities around the Skin Cancer. The DelveInsight’sReport covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Skin Cancer. DelveInsight’s Report also assesses the Skin Cancer therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note:This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.

Scope

- The report provides competitivepipeline landscape of Skin Cancer
- The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
- Coverage of the Skin Cancer pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
- The report reviews key players involved in the therapeutics development for Skin Cancer and also provide company profiling
- The report also gives the information of dormant and discontinued pipeline projects
- Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
- Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

Table Of Contents

Skin Cancer-Pipeline Insights, 2017
Illustrative

- Skin Cancer Overview
- Skin Cancer Pipeline Therapeutics
- Skin Cancer Therapeutics under Development by Companies
- Skin Cancer Filed and Phase III Products
- Comparative Analysis
- Skin Cancer Phase II Products
- Comparative Analysis
- Skin Cancer Phase I and IND Filed Products
- Comparative Analysis
- Skin Cancer Discovery and Pre-Clinical Stage Products
- Comparative Analysis
- Drug Candidate Profiles
- Skin Cancer - Therapeutics Assessment
- Assessment by Monotherapy Products
- Assessment by Combination Products
- Assessment by Route of Administration
- Assessment by Molecule Type
- Skin Cancer - Discontinued Products
- Skin Cancer - Dormant Products
- Companies Involved in Therapeutics Development for Skin Cancer
- Appendix
- Methodology
- Contact Us
- Disclaimer


List of Tables

- Number of Products under Development for Skin Cancer, 2017
- Number of Products under Development by Companies
- Comparative Analysis by Filed and Phase III Products, 2017
- Comparative Analysis Phase II Products, 2017
- Comparative Analysis Phase I and IND Filed Products, 2017
- Comparative Analysis Discovery and Pre-Clinical Stage Products, 2017
- Drug Candidates Profiles
- Skin Cancer Assessment by Monotherapy Products
- Skin Cancer Assessment by Combination Products
- Skin Cancer Assessment by Route of Administration
- Skin Cancer Assessment by Stage and Route of Administration
- Skin Cancer Assessment by Molecule Type
- Skin Cancer Assessment by Stage and Molecule Type
- Skin Cancer Therapeutics - Discontinued Products
- Skin Cancer Therapeutics - Dormant Products
- Products under Development by Companies, 2017


List of Figures

- Number of Products under Development for Skin Cancer, 2017
- Filed and Phase III Products, 2017
- Phase II Products, 2017
- Phase I and IND Filed Products, 2017
- Discovery and Pre-Clinical Stage Products, 2017
- Skin Cancer Assessment by Monotherapy Products
- Skin Cancer Assessment by Combination Products
- Skin Cancer Assessment by Route of Administration
- Skin Cancer Assessment by Stage and Route of Administration
- Skin Cancer Assessment by Molecule Type
- Skin Cancer Assessment by Stage and Molecule Type

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Implantable Infusion Pumps Market Analysis & Trends- Application (Cancer Treatment, Cancer Pain, Noncancer Pain, Spasticity, Analgesia, Mixed Sarcoma and Skin Cancers, Gastric Cancer and Diabetes Mellitus) - Forecast to 2025

Implantable Infusion Pumps Market Analysis & Trends- Application (Cancer Treatment, Cancer Pain, Noncancer Pain, Spasticity, Analgesia, Mixed Sarcoma and Skin Cancers, Gastric Cancer and Diabetes Mellitus) - Forecast to 2025

  • $ 4200
  • Industry report
  • November 2016
  • by Accuray Research LLP

The Global Implantable Infusion Pumps Market is poised to grow at a CAGR of around 6.3% over the next decade to reach approximately $14.33 billion by 2025. Some of the prominent trends that the market ...

2017-2021 France Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

2017-2021 France Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

  • $ 4350
  • Industry report
  • February 2017
  • by Venture Planning Group

Highlights Comprehensive 585-page analysis of the French tumor marker testing market.Major issues pertaining to the French laboratory practice, as well as key economic, regulatory, demographic, social ...

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

2017-2021 US Tumor Marker Testing Market: Emerging Opportunities and Growth Strategies for Suppliers

  • $ 6400
  • Industry report
  • February 2017
  • by Venture Planning Group

Complete report $9,800.  DataPack (test volumes, sales forecasts, supplier shares) $6,400. Highlights Comprehensive 620-page analysis of the US tumor marker testing market.Major issues pertaining to the ...


Download Unlimited Documents from Trusted Public Sources

Prostate Cancer Statistics in the US

  • February 2017
    14 pages
  • Prostate Cancer  

  • United States  

View report >

Cancer and Breast Cancer Statistics in Switzerland

  • February 2017
    138 pages
  • Cancer  

    Breast Cancer  

    Obesity  

  • Switzerland  

View report >

Endocrine Disease Statistics in the US

  • February 2017
    115 pages
  • Endocrine Disea...  

    Diabetes Monito...  

    Hospital  

  • United States  

    North America  

View report >

Related Market Segments :

Skin Cancer

ref:plp2017

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.